Iontronic neural interface enables much higher resolution mapping than conventional systems and when combined with leading-edge medical imaging unlocks unprecedented real-time intelligence, providing neurosurgeons with decisive functional mapping information to preserve important brain tissues during resection and to reduce time of surgery.
Toronto, Canada, and Aix-en-Provence, France, November 1, 2022 – Bioelectronic medicine company Panaxium announces that Dr. Gilles Huberfeld, MD, PhD, neurologist and researcher at Hôpital Fondation Adolphe de Rothschild, is leading the 1st humans patient investigations of its next-generation iontronic brain computer interface in 2023 in Paris, France.
The project is under the coordination of Inserm (Micro ECoGG study – Intraoperative MicroElectroCorticoGraphy of gliomas), with Dr. Michel LE VAN QUYEN, PhD., Biomedical Imaging Laboratory (INSERM U1146, Sorbonne University), and in collaboration with Hôpital Sainte Anne and Pitié-Salpêtrière Hospital in Paris, France.
Panaxium’s ultra-flexible iontronic electrocorticography (ECoG) platform will be eventually incorporated into Synaptive Medical’s Modus robotic exoscope technology to provide unparalleled real-time intelligence on bioelectrical connections and decisive functional mapping information during procedures. This will help preserve important brain tissues during resection, reduce procedure duration, and improve post-surgery outcomes for the most life-threatening brain disorders.
“The ability to build up pathological biomarker maps with micro-resolution electrocorticography over large areas of the cortex is a huge step forward for clinical research,” says Dr. Huberfeld. “The alignment of ultra-precise electrophysiological information with a patient’s surgical planning information in real-time makes the Synaptive-Panaxium solution the ultimate neuro-navigation tool for brain surgery.”
This innovation will allow neurosurgeons to obtain finer information on brain function and the impact of lesions, with better spatiotemporal resolution and better sensitivity.
For more information about Panaxium visit www.panaxium.com. For more information about this project please visit the Huberfeld Neuronal Signaling in Epilepsy & Glioma Lab website: http://www.neurosignals.eu/projects.html.
Panaxium SAS is a bioelectronic medicine company aiming to fundamentally change the way neurological disease is treated using the advantages of AI-enabled iontronic devices. The company is comprised of a multidisciplinary team of internationally renowned scientists, including world experts in organic bioelectronics and leaders in the fields of chemistry, materials science, electrical engineering, systems design, electronic engineering, data science, biology, biochemistry, and nanotechnology. Together they are working to solve some of the most difficult and important problems in medicine.